Workgroups: Public Messaging, BCI Education, & Regulatory Science Education that Could Support Policy
Date Updated: 19 October 2026
Authors: Allanah Beazley, Mark Bolding, Rob Franklin, Tamami Fukushi, Takashi Kozai, Craig Mermel, Randy Parry, Richard Phillips, Romil Singh
Overview:
This project develops an iBCI-CC response to FDA’s discussion paper on the regulation of generative AI-enabled medical devices, with a specific focus on implantable brain-computer interfaces.
The comment identifies regulatory considerations unique to BCIs while emphasizing that GenAI-specific requirements should apply to generative functions and their effects on the integrated system rather than automatically extending to non-generative neural decoding, signal processing, or routine calibration.
Key recommendations address fidelity to user intent, user-centered evaluation, evidence standards for small and individually calibrated populations, calibration and modification, privacy, and continuity of function. The goal is to provide FDA with technically grounded recommendations that support appropriate evaluation of GenAI-enabled BCI functions within existing medical device frameworks.
Audience and Application:
FDA’s Center for Devices and Radiological Health (CDRH). The document is intended for submission in response to FDA’s request for feedback and to provide BCI-specific technical and regulatory considerations that may inform future guidance, evaluation frameworks, and policy for GenAI-enabled medical devices.
